27.06.2013 Views

Voie d'immunisation et séquence d'administration de l ... - TEL

Voie d'immunisation et séquence d'administration de l ... - TEL

Voie d'immunisation et séquence d'administration de l ... - TEL

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

tel-00827710, version 1 - 29 May 2013<br />

4) Combination of t<strong>et</strong>ramer-based enrichment with intracellular staining<br />

For in vivo restimulation, mice were injected with 5µg of CpG ODN2216/ DOTAP<br />

formulated as a mixture with 1µg SIINFEKL pepti<strong>de</strong> 3 hours prior to leukocyte harvest. CpG<br />

was purchased from Invivogen, DOTAP from Roche, and the SIINFEKL pepti<strong>de</strong> from<br />

Polypepti<strong>de</strong> group. Next, the t<strong>et</strong>ramer-based enrichment protocol was performed with the<br />

addition of Brefedin-A during each incubation step. After the elution step, enriched cells were<br />

stained with Aqua as a <strong>de</strong>ad cell marker, incubated with surface staining antibodies and fixed.<br />

Next, cells were permeabilized and stained with anti-IFNγ as per the manufacturer’s<br />

instructions. Intracellular cytokine staining was performed using the Cytofix/<br />

Cytoperm/Brefeldin-A kit (BD Biosciences). For ex vivo restimulation, the t<strong>et</strong>ramer-based<br />

enrichment was performed first, and the eluted fraction was incubated 4h with SIINFEKL-<br />

pulsed splenocytes at 37°C. Then cells were stained intracellularly for IFNγ, IL-2 and TNFα<br />

(Table 8) as per the manufacturer’s instructions (BD Biosciences).<br />

B. Antibody-based enrichment<br />

Of note, a similar enrichment strategy was used to enrich TCR-transgenic CD45.1/2 WT OT-I<br />

and CD45.2/2 IFNAR -/- OT-I that were transferred into CD45.1/1 WT recipient mice using a<br />

anti-CD45.2-PE staining of leukocytes rather than PE-labeled K b -SIINFEKL t<strong>et</strong>ramers.<br />

C. IFNγ ELISPOT<br />

At different time points following immunization, the spleen and the draining lymph no<strong>de</strong><br />

were harvested and CD8 + T cells were purified using anti-CD8 microbeads and MS columns<br />

(Miltenyi Biotech). IFNγ ELISPOT was performed as previously <strong>de</strong>scribed (Blachere <strong>et</strong> al.,<br />

2006). The Elispot plate evaluation was performed in a blin<strong>de</strong>d fashion by an in<strong>de</strong>pen<strong>de</strong>nt<br />

evaluation service (Zelln<strong>et</strong> Consulting) using an automated ELISPOT rea<strong>de</strong>r (Carl Zeiss).<br />

D. Cytotoxicity in vivo<br />

CD45.1 splenocytes were prepared. Half of them were stained with 0.5µM<br />

carboxyfluorescein diac<strong>et</strong>ate succinimidyl ester (CSFE) using the Vybrant cell tracer kit from<br />

Invitrogen, and pulsed with SIINFEKL pepti<strong>de</strong>. The other half were stained with 5µM CFSE<br />

and left unpulsed. At different time points following immunization, mice received i.v. 5x10 6<br />

of cells from each of these pools. 15 hours later, spleen was harvested and cells were stained<br />

184

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!